Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a US-based biopharmaceutical company, announced on Wednesday that it has named Colleen Delaney, MD, MSc as its new chief scientific and medical officer.

The appointment is subsequent to the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.

Dr Delaney has over two decades of experience as a trained oncologist and stem cell transplant physician scientist. She has served on multiple cell and gene therapy focused federal advisory committees and as a director for several nonprofit associations. She has also served as a clinical professor at the University of Washington, Division of Pediatric Hematology/Oncology, and is an affiliate and former professor at the Fred Hutch, where she also served as the Madeline Dabney Adams endowed chair in AML research.

Dave Mehalick, Coeptis Therapeutics president and CEO, said, 'Dr Delaney is a visionary researcher who has dedicated her life to patients as a practicing physician and through her career as a global leader advancing all aspects of cell therapy product development. Colleen's work with Deverra and the impressive pipeline of technologies she developed demonstrate her ingenuity and scientific acumen. Coeptis is excited to benefit from Colleen's unrivalled expertise and industry knowledge as we seek to maximise the combined technologies of Coeptis and Deverra to bring to the market impactful off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases.'